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Abstract
Drug resistance is a major problem in health care, undermining therapy outcomes and 
necessitating novel approaches to drug design. Extensive studies on resistance to viral protease 
inhibitors, particularly those of HIV-1 and hepatitis C virus (HCV) protease, revealed a plethora of 
information on the structural and molecular mechanisms underlying resistance. These insights led 
to several strategies to improve viral protease inhibitors to counter resistance, such as exploiting 
the essential biological function and leveraging evolutionary constraints. Incorporation of these 
strategies into structure-based drug design can minimize vulnerability to resistance, not only for 
viral proteases but for other quickly evolving drug targets as well, toward designing inhibitors one 
step ahead of evolution to counter resistance with more intelligent and rational design.
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Drug Resistance and Viral Proteases as Drug Targets
Drug resistance is a major health burden in a wide range of diseases from cancer to bacterial 
and viral infections, causing treatment failure as well as severe economic impact on the 
healthcare system. Drug resistance can be conferred via various mechanisms including 
decreased intracellular levels of drug such as due to efflux pumps, altered gene expression, 
and changes in drug target [1–4]. The most common mechanism of resistance to drugs 
against quickly evolving targets involves mutation of the targeted protein, including 
resistance to small molecule inhibitors of viral proteases.
Viral proteases are ideal drug targets as they are essential in the viral life cycle, and 
inhibiting the viral protease prevents the generation of new infectious viral particles. Most 
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viruses that infect humans and cause disease encode at least one viral protease [5, 6]. These 
proteases are responsible for cleaving the viral polyprotein precursors at specific sites to 
release individual functional proteins, including cis cleavage of the protease itself. Certain 
viral proteases have also been reported to cleave host cell proteins such as translation 
initiation factors (eIF4 and eIF3d) in HIV to inhibit host protein translation [7, 8], and 
transcription factors in hepatitis C virus (HCV) to confound the innate immune response [9]. 
Although most viral proteases share general backbone folds and catalytic mechanisms with 
host cellular proteases, they are generally more compact likely due to evolutionary pressure 
to maintain a small genome [6]. Nevertheless, viral proteases are able to recognize and 
cleave diverse substrate sequences with distinct specificities.
HIV-1 and HCV Protease Inhibitors
Among medically relevant viruses, the viral protease most extensively investigated is 
inarguably the aspartyl protease encoded by HIV-1, with hundreds of sequences in the 
Stanford Database and crystal structures in the Protein Data Bank [10, 11]. HIV-1 protease is 
comprised of two identical chains of 99 amino acids each, with the active site located at the 
dimer interface and each monomer contributing a catalytic Asp to the active site (Figure 1a). 
In the unliganded state, HIV-1 protease is symmetric with highly flexible flaps that allow 
access to the active site. In the liganded state, these flaps close upon the bound substrate or 
inhibitor at the active site and become much more rigid. HIV-1 protease has been the target 
of extensive drug discovery and development efforts for decades and had a major role in 
launching the field of structure-based drug design. These efforts resulted in 9 FDA-approved 
HIV-1 protease inhibitors (PIs). All HIV-1 PIs are competitive inhibitors that bind at the 
protease active site. Although these PIs are very effective in inhibiting the wild-type protease 
and have significantly contributed to clinical treatment outcomes in combination therapy 
[12–14], resistance has emerged to all HIV-1 PIs.
HCV, which infects millions of people worldwide and causes chronic liver disease, liver 
failure and liver cancer [15, 16], encodes a chymotrypsin-like serine protease, NS3/4A 
(Figure 1b). HCV NS3/4A protease is a prime therapeutic target for direct-acting antivirals, 
with four FDA-approved inhibitors [17–21] and several in various stages of clinical 
development. However, even before the drugs were approved for the clinic, resistant viral 
variants have emerged [22–24]. Rapid emergence of resistance and low efficacy against 
genotypes other than HCV Genotype 1 has mandated combination therapies, which also 
decreased treatment duration and increased cure rates especially for Genotype 1 [25–27].
Mutations Confer Resistance by Selectively Weakening Inhibitor Binding 
but Retaining Specific Substrate Recognition and Cleavage
For a virus to become resistant to a PI, the viral genome acquires mutations that allow the 
protease to thwart inhibition by the drug but still retain the ability to cleave the viral 
polyprotein substrate at the required specific sites to allow viral maturation. HIV-1 evolves 
rapidly due to a high viral replication rate (107–109 newly infected cells/day in a patient 
[28]) and the error-prone mechanism of the viral reverse transcriptase, which generates a 
diverse pool of viral variants. This rapid evolution enables the targeted viral protease to 
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acquire mutations that abrogate the efficiency of inhibitor–protein binding. Many mutations 
already pre-exist at low levels even before the start of therapy in infected patients, and 
quickly become selected under drug pressure. Critically, these selected protease variants still 
retain their substrate recognition and cleavage activity and allow viral propagation. HIV-1 
protease needs to process the Gag and Gag-Pro-Pol polyproteins at nine distinct sites, while 
HCV NS3/4A protease cleaves viral polyprotein precursors at four cleavage sites and 
cleaves two human immune proteins to confound the innate immune response. However, 
these cleavage sites are highly diverse in amino acid sequence, and unlike most known 
human proteases, the viral proteases do not have simple substrate sequence recognition 
motifs.
How is a viral protease able to recognize and cleave apparently dissimilar substrates with 
high specificity? And how can the targeted protease mutate to avoid inhibition but still 
process these substrates? The answer to these questions for HIV-1 protease led to major 
breakthroughs in elucidating molecular mechanisms underlying selection of primary 
mutations in drug resistance.
Substrate Envelope Explains Selection of Active Site Resistance Mutations
Although not similar in amino acid sequence, the substrates cleaved by HIV-1 protease all 
occupy a similar ‘shape’ or volume when bound at the active site, as revealed by high-
resolution crystal structures of protease-bound peptides corresponding to cleavage sites in 
the viral polyprotein [29, 30]. Hence, the recognition motif for the viral protease is not a 
particular amino acid or sequence but a common shape assumed by the substrates, termed 
the substrate envelope (Figure 2). Similarly, the substrate envelope for HCV NS3/4A 
protease has also been determined as the overlapping volume shared by bound peptides in 
complex crystal structures [31] (Figure 3).
In addition to explaining how the viral proteases recognize their substrates, the substrate 
envelope effectively explains the mechanism of resistance due to active site mutations. 
Active site residues that make essential and conserved interactions with the substrate, 
including the catalytic side chains, cannot mutate to confer resistance without compromising 
substrate binding. However, whenever an inhibitor protrudes beyond the substrate envelope 
to contact a protease residue, that residue can mutate to differentially weaken contact with 
the inhibitor relative to substrate binding resulting in drug resistance. Accordingly, specific 
resistance mutations near the viral protease active site that confer resistance to a given 
inhibitor occur at positions where that inhibitor protrudes beyond the substrate envelope to 
make contact with the enzyme (Figure 2) that are not necessary for substrate recognition but 
compromise inhibitor binding.
Correlations between active site resistance mutations and protrusion of a specific inhibitor 
out of the substrate envelope have been demonstrated for a variety of HIV-1 and HCV PIs 
[29, 31–34]. HIV-1 protease signature resistance mutations (such as D30N to nelfinavir, 
I50V/L to amprenavir/atazanavir, G48V to saqunavir, and V82A to saquanavir/ritonavir) all 
occur where that particular inhibitor contacts the protease active site beyond the substrate 
envelope (Figure 2). Similarly, the major HCV NS3/4A protease resistance mutations occur 
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in the S2 pocket residues (R155, A156, and D168) that are contacted by large P2 extension 
moieties protruding out the substrate envelope [24, 31]. Hence, a structural analysis of the fit 
of a given inhibitor within the viral protease substrate envelope is a good predictor of active 
site residues that may mutate to confer resistance to that inhibitor.
Strategies in Designing Against Resistance
Drug design typically focuses on improving affinity against a single target of interest, 
typically the wild-type variant of the most common genotype in the case of viral proteases. 
Indeed, all the HIV-1 PIs have been designed on wild-type HIV-1 subtype B, the dominant 
viral strain in Europe and the Americas. Inadvertently, this current drug design paradigm 
may actually facilitate the occurrence of drug resistance, since the standard process is to 
develop potent compounds that very specifically target the wild-type structure of a single 
subtype. Polymorphisms in other subtypes can severely impact inhibitor potency and lead to 
different pathways to resistance, as seen in HCV genotype 3 [35] and HIV-1 [36]. Disrupting 
the activity of a single wild-type target is necessary, but not sufficient, for developing a 
robust drug that avoids resistance. Instead of trying to combat resistance only after resistant 
viral variants arise in clinic, we need a paradigm shift to incorporate elucidation of drug 
resistance mechanisms to the design strategy.
Detailed analysis of molecular resistance mechanisms for HIV-1 and HCV viral PIs has led 
to several strategies that can be incorporated into the design strategy toward more robust 
inhibitors, which should extend to other rapidly evolving drug targets (Box 1).
The first strategy is to design inhibitors that fit within the substrate envelope. This strategy 
originates from the realization that substrate envelope efficiently explains susceptibility to 
resistance due to active site mutations. As protrusions out the substrate envelope render an 
inhibitor vulnerable to resistance, avoiding such protrusions will minimize the chances of 
active site mutations that can confer resistance. Analogous pairs of inhibitors designed to 
stay within versus extend beyond the substrate envelope supported this strategy [37]. 
Darunavir (DRV) is the proof-of-concept for the viability and validity of this strategy and is 
the most potent and robust HIV-1 PI in the clinic [38–40]. Although not designed according 
to the substrate envelope, DRV fits very well within HIV-1 protease substrate envelope, 
avoiding unessential contacts that would render the inhibitor susceptible to resistance 
mutations. Accordingly, no single or even double mutation confers significant DRV 
resistance; protease needs to extensively evolve to accumulate at least ~7 mutations to 
escape DRV inhibition in vitro at therapeutic concentrations [38, 41]. In clinical trials, 11 
mutations in protease were associated with resistance to DRV and the presence of at least 3 
of these mutations was associated with a diminished virological response to this drug [42]. 
DRV also proves that achieving high potency (single digit picomolar) while staying within 
the substrate envelope is possible.
How widely applicable is the design strategy of using the substrate envelope to counter 
resistance due to active site mutations? Both HIV-1 and HCV proteases have diverse 
substrates that are recognized by shape, which defines the envelope. Similarly, most viral 
proteases also lack a sequence-based recognition motif and process diverse substrates that 
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also likely bind to protease in a conserved shape. However, multiple or diverse substrates are 
not a prerequisite to define a substrate envelope for a given target. The key to this strategy is 
to define target-substrate contacts (even for a single natural substrate) that are essential for 
biological function, and avoid any contacts beyond those in inhibitor design.
A complementary strategy in identifying residues that are essential to the target’s biological 
function is exploiting knowledge on sequence conservation. Whether with or without 
selection pressure, the viral protease can evolve only if the enzyme maintains residues 
essential for function, including the catalytic residues. Designing inhibitors that pack on 
these strictly conserved residues minimizes chances of mutations that the enzyme can 
tolerate to confer resistance. The HCV NS3/4A PI MK-5172 is a good example where the 
extended P2 moiety protrudes out the substrate envelope but packs on the catalytic residues 
(rather than the mutation-prone S2 subsite) (Figure 3). In addition to the catalytic residues, 
other regions that cannot tolerate mutations can be identified by sequence alignment or by 
systematic probing of the mutational fitness landscape through saturating mutagenesis [43, 
44]. In such an analysis, all possible point mutations can be introduced into the protease and 
the effect on enzymatic fitness measured. Residues that cannot tolerate mutations without 
compromising fitness may have less chance of mutating to confer resistance.
One strategy in designing against resistance is maximizing hydrogen bonds of the inhibitor 
with main chain atoms of active site residues. The idea here is that the protease backbone 
atoms are invariant regardless of the side chain, which can change due to a mutation [45, 
46]. While less likely than a side chain hydrogen bond, main chain hydrogen bonds can still 
be readily lost due to steric effects or shifts in the inhibitor-binding mode due to side chain 
changes. Therefore, this strategy may be the most effective when the binding mode of 
natural substrates is taken into consideration, by either mimicking the hydrogen bonds of 
natural substrates or making sure the inhibitors do not violate the substrate envelope 
constraints.
Another strategy against resistance, proposed for both HIV-1 protease and reverse 
transcriptase and may be more generally applicable, is designing flexibility into the 
inhibitors so that they can slightly shift or change conformation in response to active site 
mutations [47–50]. One key caveat in applying this strategy may be having an ‘anchor’ 
moiety with extensive interactions that are invariant, which can help ensure sustained 
potency even when part of the inhibitor adapts in response to the mutation.
Increasing Potency to Avoid Resistance
Although common practice is to report fold-changes in affinity (Ki or IC50 values) with 
respect to wild-type protease, the absolute value of affinity against a given variant is what 
determines resistance at a given drug concentration. For instance, DRV has a Ki in the low 
picomolar range against wild-type HIV-1 protease. Even with a 10 or 100-fold change due to 
a mutation, DRV may still be more potent against a ‘resistant’ variant compared to other 
inhibitors with much lower affinity. Hence, increasing potency of a viral PI contributes to the 
barrier to resistance.
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Potency of PIs can benefit from additional design strategies based on recent findings, in 
addition to standard structure based drug design. First, inhibitors can be modified to more 
optimally fill the substrate envelope, without compromising low susceptibility to resistance. 
For example, the P1’ moiety in DRV can be extended without violating the substrate 
envelope, a strategy that resulted in inhibitors even more potent and more robust than DRV 
[51–53]. Similarly, a comparison of HCV NS3/4A inhibitors with the substrates reveals a 
large portion of the substrate envelope in the P4-P5 region not utilized by any current 
inhibitor [54] (Figure 3). Extending inhibitors to this untapped region of the protease active 
site can enhance inhibitor potency. Another strategy that significantly enhanced HCV PI 
potency is adding a macrocycle to link either the P2–P4 or P1–P3 moieties [55–57]. The 
macrocycle is thought to stabilize the inhibitor in a conformation competent for protease 
binding, thus increasing the entropic contribution to the free energy of binding. However, 
macrocycle design may need to be optimized between the rigidity required for enhancing 
entropy versus the flexibility required for adapting to a mutated active site [55, 58].
Can Resistance-Proof PIs Be Designed?
PIs of HIV-1 have two unique advantages toward becoming resistance-proof: (i) PIs have 
highly cooperative dose-response curves. This implies that at clinical levels of drug 
concentration, which is typically much higher than IC50 values, very high levels of (or 
complete) enzyme inhibition can be achieved [59–61]. (ii) PIs are the only transition-state 
analogs among direct-acting antivirals (DAAs). As transition-state analogs, HIV-1 PIs have 
unprecedented potential to achieve exceptional potencies, as enzymes have evolved to bind 
tightest to the transition state.
In clinical practice, emergence of drug resistance by HIV-1 is successfully thwarted by 
multidrug therapy where the rapid addition of high levels of a combination of drugs presents 
a high enough genetic barrier so that resistance does not develop. This happens even though 
resistance would evolve to each of the drugs if they were given sequentially and additively. 
This clearly shows that there is a limited sequence space the virus can occupy during the 
time of therapy initiation, and that there is not enough time (i.e. rounds of replication) to 
explore greater space during the period when viral load is falling in the presence of multiple 
drugs. Even though there is no imminent effort to completely replace multidrug therapy with 
a single inhibitor, the possibility of a ‘resistance-proof protease inhibitor’ is a compelling 
concept, and may find clinical use in maintenance therapy.
As increasingly potent transition state analogs are developed, the threshold may be crossed 
where the potency is so high that the addition of one, two, or three resistance mutations does 
not confer a useful level of resistance and thus does not allow sustained replication. This 
approach could lead to a path where single drug therapy could be a viable option in a 
maintenance strategy for treatment-naïve patients, greatly reducing the cost of lifelong 
therapy. In fact, therapy failure with DRV in such individuals is rarely associated with drug 
resistance mutations [62], suggesting that failure is primarily due to compliance or extreme 
metabolism of the drug. In few patients where DRV-containing regimens as first line of 
therapy fail, in addition to no mutations in the protease, the reverse transcriptase resistance 
mutations were only rarely observed [63]. Hence, DRV may be close to an inhibitor where 
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the appearance of the first resistance mutation is insufficient to confer enough of a growth 
advantage to allow evolution of subsequent resistance mutations, and further improvements 
in inhibitor potency could lead to resistance-avoiding PIs. A recent clinical study actually 
found DRV monotherapy to be acceptable for long-term management of HIV infection, with 
regular viral load monitoring and prompt reintroduction of combination treatment for those 
who rebound [64]. However, considering the scarcity of data on inflammation and clinical 
progression, long-term DRV monotherapy needs to be administered with caution and only in 
selected patients, and we may need to even further improve pharmacokinetics, potency and 
clinical outcomes for long-term PI monotherapy.
Remaining Challenges in Overcoming Resistance
While we have considerable knowledge on the molecular mechanisms underlying resistance 
conferred by various protease mutations, still multiple challenges remain in understanding 
and overcoming PI resistance (see Outstanding Questions). In many drug resistant protease 
variants, multiple mutations co-evolve to both decrease the affinity of a particular inhibitor, 
and increase the viability and fitness of the enzyme. In HCV, a single mutation is often 
enough to confer resistance to PIs, but variants with multiple mutations can be found in 
clinical samples, as well as multiple changes in amino acid sequence (polymorphisms) 
across different genotypes. In HIV-1, multi-drug resistant patient isolates contain multiple 
mutations with up to 25% of the amino acids in the enzyme able to mutate and contribute to 
resistance [65, 66]. The impact of such combinations of mutations on conferring drug 
resistance is not simply additive, but instead these mutations can have complex 
interdependent effects [67, 68]. One remaining challenge is to unravel the interdependency 
of multiple mutations in conferring drug resistance.
Another challenge is revealing the molecular mechanisms of resistance conferred by 
mutations at residues outside of the active site (Figure 4). While the substrate envelope 
efficiently explains the selection of active site mutations, the mechanism of resistance 
associated with mutations outside the active site still remain elusive. Mutations distal to the 
active site may compensate for the losses in enzymatic fitness or protein conformational 
stability due to the active site mutations [69, 70]. In HIV-1 protease, many of these 
mutations are known to compensate for enzymatic fitness, but these and others may also 
directly confer resistance. Residues outside the active site that mutate to confer resistance 
are in the flaps (M46, F53, and I54) and core of the enzyme (L24, L33, L76, N88, and L90). 
In HCV protease, the distal mutation V36M is commonly associated with resistance [71]. 
Incorporating the effect of such distal mutations into rational drug design remains a 
complete challenge. The effect of mutations away from the active site may be propagated to 
the active site through a network of interactions within the protease, similar to a domino 
effect, as suggested by a detailed analysis of changes in the interaction network of HIV-1 
protease structure due to such mutations (Figure 4A) [72].
While explaining the mechanism by which such mutations outside the active site confer 
resistance is challenging, one likely mechanism is through alterations in protein dynamics 
(Figure 4B). HIV-1 protease is a flexible enzyme that undergoes extensive conformational 
changes to allow opening of the flaps and access to the active site [73–76]. These changes at 
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the flaps are coupled to extensive side chain repacking at the hydrophobic core, or 
hydrophobic sliding [77, 78]. Mutations that cause changes in this dynamic process can 
confer resistance by altering the balance between substrate processing versus inhibitor 
binding at the active site. Altered dynamics differentially impact substrate processing versus 
inhibitor binding, as the inhibitor needs to stay bound at the active site for efficient 
inhibition, while the substrates need to be processed and released for efficient turnover. Such 
changes in dynamics have been revealed in molecular dynamics simulations as well as 
experimental NMR and electron paramagnetic resonance (EPR) dynamics of HIV-1 protease 
drug resistant variants [79–82]. This resistance mechanism through changes in 
conformational dynamics propagating to the active site [72] may be common to distal 
mutations in other proteases.
Mutations in other viral proteins beyond protease can contribute to drug resistance. Viral 
maturation is a complex interdependent process where additional levels of resistance can 
occur due to mutations in other viral proteins, and especially the protease cleavage sites in 
the Gag and Gag-Pro-Pol polyproteins. Mutations in the HIV-1 Gag polyprotein co-evolve 
with primary resistance mutations in the protease [83–87] and some mutations can even 
directly confer resistance in the absence of protease mutations [85, 88–90]. Thus drug 
resistance occurs within a complex system of interactions between the protease and the viral 
and host substrates; with the interdependent mechanisms by which changes outside the 
protease contribute to resistance remaining to be elucidated. Whether there are certain key 
signature mutations and/or common mechanisms through which resistance is conferred in 
highly mutated viral variants is still to be explored.
Concluding Remarks
To avoid resistance, the design of inhibitors against viral proteases needs to consider the 
essential biological function and evolutionary constraints on the protease. This entails design 
not just against the wild-type target but considering all potential mutant variants that can 
exist and still carry out the protease’s biological function. Combining strategies to minimize 
vulnerability to resistance while enhancing potency can lead toward designing inhibitors that 
are more robust against resistance. Regardless of whether ‘resistance-proof’ inhibitors are 
achievable or not, lessons from HIV-1 and HCV proteases can be incorporated into 
structure-based drug design. Reaching ‘resistance-avoiding’ inhibition is achievable given 
the constraints on viral evolution as the population size plummets with the initiation of 
potent therapy. Instead of lagging behind evolution and waiting for resistance to emerge, we 
can move one step ahead of evolution to counter resistance with more intelligent and rational 
design.
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Box 1. Strategies to Design Potent Viral PIs Robust Against Resistance
Figure I. Depiction of Strategies for Design of Inhibitors to Prevent Resistance
The substrate envelope of viral proteases can be incorporated into structure-based drug 
design to minimize the vulnerability of inhibitors to the emergence of resistance. The 
main strategies to design resistance-avoiding PIs include:
1. Stay within the substrate envelope: avoid contacts with protease residues 
(red bar) beyond those of the natural substrate(s).
2. Extend beyond the substrate envelope only if contacting invariant conserved 
residues such as the catalytic side chains (green bar), or toward the solvent.
3. Exploit untapped regions of the substrate envelope to further increase 
potency.
4. Add macrocycles to preposition the inhibitor in a binding-competent state, 
making sure the macrocycle itself obeys the rules above.
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Outstanding Questions
• How do mutations outside the protease active site confer resistance? What 
is the molecular mechanism by which the impact of such mutations 
propagates to the active site?
• How is protein conformational dynamics related to drug resistance? Can we 
predict resistance from changes in dynamics?
• Are there key signature mutations that are pivotal in conferring resistance in 
highly mutated protease variants, and/or redundant mutations? Is there 
interdependency or synergy between coexisting mutations? Can we design 
inhibitors to avoid them?
• Can predictive and quantitative models of drug resistance be developed 
based on the kinetic balance between inhibitor binding versus substrate 
processing? Can the effect of multiple mutations in the protease, substrates 
sites, and other viral components be incorporated in the models?
• Is a ‘resistance-proof protease inhibitor possible? Is there a reachable 
potency threshold beyond which a protease inhibitor avoids clinical 
resistance?
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Trends Box
• Viral proteases recognize substrates through a conserved shape, defining the 
substrate envelope.
• A variant that does not bind inhibitors efficiently but still processes 
substrates is resistant.
• Resistance mutations occur where inhibitors protrude outside of the 
substrate envelope.
• High potency inhibitors that fit within the substrate envelope can avoid 
resistance.
• Resistance-avoiding strategies need to be included in structure-based drug 
design.
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Figure 1. 
HIV-1 and HCV Protease Structures. (A) HIV-1 protease bound to darunavir (PDB: 1T3R). 
The two monomers of HIV-1 protease are in light purple and gold. (B) HCV NS3/4A 
protease bound to MK-5172 (PDB: 3SUD). The inhibitors are in magenta and the catalytic 
residues in yellow sticks.
Yilmaz et al. Page 17
Trends Microbiol. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Substrate Envelope of HIV-1 Protease and Fit of PIs in the Envelope. (A) The substrate 
envelope (teal volume) displayed at the active site of HIV-1 protease (light purple and gold 
ribbons), and (B) top view of this. (C) The fit of protease inhibitors darunavir (DRV, red 
sticks) and saquinavir (SQV, magenta sticks) in the substrate envelope. The side chain of 
protease residue V82, which mutates to A to confer resistance to SQV, is displayed as green 
sticks and mesh surface.
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Figure 3. 
Substrate Envelope of HCV NS3/4A Protease and the Fit of PI MK-5172 in the Envelope. 
(A) The substrate envelope (teal volume) displayed at the active site of HCV protease (light 
purple ribbon). The catalytic side chains are in yellow sticks. (B) The fit of protease inhibitor 
MK-5172 (magenta sticks) in the substrate envelope. The protease is displayed as a gray 
surface, with catalytic residues (yellow) and residues at the S2 subsite (purple, green, and 
red) that mutate to confer resistance colored on the surface. The large P2 extension moiety 
of MK-5172 protrudes beyond the envelope but avoids contacts with the S2 residues and 
instead packs against the catalytic residues.
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Figure 4. 
Mutations Remote From the Active Site Can Contribute to Conferring Resistance. (A) The 
network hypothesis postulates that the impact of mutations away from the active site can be 
transmitted to the active site via the network of hydrogen-bonded interactions in the protein 
(dashed lines, displayed on one monomer of HIV-1 protease). (B) HIV-1 protease is highly 
dynamic, as revealed in snapshots from MD simulations, and mutations may modulate 
ligand binding to confer resistance by altering such conformational dynamics.
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